Contracts coming in thick & fast
Today almost every organization is having to respond to the data arms-race, with the desire to...
Read moreAnti-microbial agents with unique properties
Following the set of largely established US and EU guidelines which recommend the decolonisation of...
Read more
Foundations laid for further growth
In October 2019, Impax reported impressive AUM growth, closing FY19 on £15.1bn, up 21% on FY18 (AUM...
Read moreFull-year results
Oxford Biodynamics’ EpiSwitch platform has won widespread recognition this year, including a fifth...
Read moreOn track to hit FY20 expectations
Success in business, investing and life in general revolves around seizing opportunities, whilst...
Read moreOn the road towards mainstream adoption
Occasionally on the FTSE, there can be such a wide disconnect between price & value that it is...
Read moreEncouragement from interims
ReNeuron Group plc is an AIM listed biotechnology company developing allogeneic cell therapies. Its...
Read moreGrowth outlook remains sweet
Cake Box, which announced strong interim results today, benefits from a unique value for money...
Read moreNow the dust has settled
ReNeuron Group is an AIM listed biotechnology company developing allogeneic cell therapies. Their...
Read moreGrowth, profitability, opportunity
Tatton, the UK's largest provider of on-platform discretionary fund management services to IFAs,...
Read more
Register to be first
Get research on the companies that interest you straight to your inbox
